Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Astra Scaling Up To 2 Million Doses Per Week "Imminently"

Wed, 13th Jan 2021 13:03

(Alliance News) - AstraZeneca is "imminently" scaling up to release 2 million doses of its vaccine per week in the UK, and may be able to go above that from April, the firm's chief executive has said.

Tom Keith-Roach, president of AstraZeneca UK, said 1.1 million doses of the company's Covid-19 jab developed with Oxford University had been released to the UK to date, but the aim was to reach two million doses per week on or before the middle of February.

He told the Commons Science and Technology Committee: "We are scaling up very rapidly – and this will happen imminently – to releasing two million doses a week.

"We're absolutely on track to do that and therefore deliver tens of millions of doses in the first quarter of the year.

"If we average two million a week through the course of the year, that gets us to the 100 million doses that we're committed to the UK through the course of 2021."

Later, he added: "We are scaling up to two million doses a week imminently and we'd certainly hope to be there on or before the middle of February."

He said the middle of February was a "conservative position" and said the firm had been asked by the UK Vaccines Taskforce "not to share in public forum in detail daily delivery schedules and locations for security reasons.

"As you can imagine it's very sensitive, but I can reassure you that we will scale to two million doses per week very quickly."

Later, he said the firm could not commit to doses above two million per week but it may be they could "increase that somewhat as we move into quarter two".

Keith-Roach also told MPs the "vast majority" of the fill-and-finish packing around the vaccines is done in the UK.

He said the manufacture of the vaccine depends on a complex biological process which cannot be carried out more quickly.

"Drug substance manufacture is a 58 to 60-day process that you cannot speed up – that is a complex biological process of actually growing the adenovirus vector," he said.

Mene Pangalos, executive vice president of biopharmaceuticals research and development at AstraZeneca, added: "You have to grow cells and cells divide at a certain speed, and you can't do any faster than the speed at which the cells divide."

Keith-Roach added: "From drug substance, you have to actually manufacture the drug product.

"That includes filling and finishing, packaging, batch release – that takes a further 28 days.

"If you look in total, you're talking about a three to four-month process.

"Within that you have, as you'd imagine, extensive quality testing on every batch – actually there's more than 60 quality tests that are performed."

Vaccines minister Nadhim Zahawi was accused by Labour MP Graham Stringer of being "phobic" to the numbers and keeping data on vaccine supplies "secret".

Zahawi said "this idea that we are sitting on lots of stock is not true", adding that deliveries of central stocks were unpredictable at the moment.

He told MPs the initial vaccination supply had been "lumpy" but he now had "line of sight" of deliveries to the end of February.

"In any manufacturing process, especially one where you're dealing with a biological compound, a novel vaccine is lumpy at the outset," he said.

"There's no doubt that it was, but getting better. It begins to stabilise and you get much clearer line of sight.

"I now have line of sight of deliveries all the way through until end of February and getting more confidence about March as well.

"We have millions of doses coming through in the weeks and then next month and the month after."

He added that "day by day, what you'll see is greater volumes going out", saying there would be "day-by-day" improvements in the notice given to vaccinators such as GPs of when supplies will arrive.

And he denied reports that vaccines could not be supplied to the NHS on a Sunday, adding there was a 98.5% accuracy to date in the timing of deliveries.

He also said the amount of vaccine currently going to waste in the NHS was significantly less than the 10% forecast by NHS England.

Earlier, Pangalos said research had begun to examine the mixing of different vaccines to allow greater flexibility in the system.

"(It's) something that we're starting to investigate already, both pre-clinical and clinically."

He also called for people working in the vaccine process to be prioritised for jabs.

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.